How to Get Ketamine Therapy: Clinics, Costs & Coverage

Ketamine therapy for depression is available through two main channels: FDA-approved esketamine nasal spray, administered under supervision at certified treatment centers, and off-label intravenous or oral ketamine, offered at independent ketamine clinics and through some telehealth providers. How you access it, what you pay, and whether insurance helps all depend on which form you pursue. The gap between those two paths is wider than most people expect, and understanding it before you call a clinic saves real time and money.

FDA-Approved Esketamine Versus Off-Label Ketamine

The distinction that shapes everything about cost and access is the difference between esketamine and ketamine. Esketamine (brand name Spravato) is a nasal spray that received FDA approval in 2019 for treatment-resistant depression.¹ Because it has an FDA indication for depression, it can be listed on insurance formularies, billed with standard codes, and prescribed through a structured program with specific safety requirements. Patients must self-administer the spray in a certified healthcare setting and be monitored for at least two hours afterward.

Generic intravenous ketamine, by contrast, is FDA-approved only as an anesthetic. When clinics use it to treat depression, anxiety, PTSD, or chronic pain, that use is off-label. Off-label prescribing is legal and common across medicine, but it means insurers can decline coverage by labeling the treatment “experimental.”² This single regulatory distinction creates two very different experiences for patients trying to get treatment.

What Delivery Methods Are Available

If you start researching ketamine therapy, you will quickly encounter a range of formulations. Each one reaches the bloodstream at different rates and in different amounts, which affects both how the session feels and how it is supervised.

Intravenous (IV) infusion: Delivered directly into a vein over roughly 40 minutes to an hour. This is the most studied route for depression and gives clinicians precise control over dosing. It requires an in-clinic visit with medical staff present.
Intranasal spray: Esketamine (Spravato) is the FDA-approved version. Generic ketamine can also be compounded into a nasal spray. In a pharmacokinetic comparison, nasal delivery had the highest bioavailability among non-IV routes, estimated at about 45%.³
Sublingual tablets or troches: Dissolved under the tongue, these are often used in at-home ketamine programs. Bioavailability is roughly 30%, meaning a larger dose is needed to achieve therapeutic blood levels compared to IV or nasal routes.³
Oral tablets: Swallowed rather than dissolved under the tongue. Bioavailability drops to about 20% because the liver metabolizes much of the drug before it reaches the brain. This route produces more of the active metabolite norketamine relative to ketamine itself.
Intramuscular injection: A shot into muscle, sometimes used in clinic settings as an alternative to IV when vein access is difficult. Onset is slower than IV but faster than oral routes.

Non-IV formulations of generic ketamine, particularly sublingual and oral versions, have attracted attention because they make treatment possible outside hospital-style settings. A review of the evidence noted that these routes may offer more realistic access for patients who face cost barriers or live far from IV clinics, though the evidence base for non-parenteral formulations is still limited compared to IV ketamine.⁴

Finding a Clinic and What to Expect

Ketamine clinics have opened rapidly in most major U.S. metro areas over the past several years. Some are embedded within psychiatric practices or academic medical centers; others are standalone infusion centers. The variation in how these clinics operate is wide, so knowing what a well-run clinic looks like is worth your attention before booking.

A responsible clinic begins with a thorough screening. Published guidelines for setting up an IV ketamine clinic emphasize standard operating procedures that include an initial psychiatric and medical assessment, clear dosing protocols, and safety monitoring procedures throughout the infusion.⁵ At minimum, you should expect a detailed intake that reviews your psychiatric history, current medications, substance use history, cardiovascular health, and any history of psychosis or mania. Clinics that skip this step or offer treatment after only a brief online form should raise a red flag.

During an IV infusion, you will sit in a recliner or lie on a bed while the drug is administered through an IV line. Staff should monitor your blood pressure at regular intervals. Ketamine can cause transient spikes in blood pressure, and psychiatry guidelines recommend regular monitoring with a clear plan for managing those episodes.⁶ You will likely feel dissociated, possibly experience visual distortions, and may feel nauseous. Most people describe the experience as dreamlike. The effects wear off within an hour or two after the infusion ends, but you should not drive for the rest of the day.

When evaluating a clinic, look for a few practical things. Is a physician, nurse practitioner, or physician assistant present during your session, or just a medical assistant? Does the clinic have crash cart equipment or at least basic emergency supplies? Will they communicate with your existing psychiatrist or therapist about your treatment? And are they transparent about their pricing before your first visit? A clinic that is evasive about cost is a clinic that has learned patients often experience sticker shock.

How Much Ketamine Therapy Costs

Cost is the single biggest barrier for most people considering ketamine therapy. A single IV ketamine infusion at a private clinic typically runs between $400 and $800, and a standard initial course involves multiple sessions. Prices vary by region, with clinics in major coastal cities often charging at the higher end.

Esketamine (Spravato) carries a high list price as a branded pharmaceutical, but because it has an FDA indication, insurance often covers a portion. A cost-effectiveness analysis comparing the two treatments found that from the healthcare system’s perspective, IV ketamine actually produced better outcomes at lower total cost than esketamine. But from the patient’s out-of-pocket perspective, esketamine could end up costing less because insurance absorbs much of the expense.⁷ This is one of the stranger dynamics in ketamine therapy: the treatment that costs the healthcare system more per patient may cost you less if your insurance covers it.

For people paying entirely out of pocket for IV ketamine, the initial course of six infusions over two to three weeks can total $2,400 to $4,800. Maintenance infusions, needed by many patients to sustain improvement, add ongoing costs of several hundred dollars per month. Some clinics offer package pricing or financing plans, and a few have sliding-scale fees, but these are not universal.

The Insurance Coverage Gap

Insurance coverage for ketamine therapy depends almost entirely on whether you are pursuing esketamine or generic ketamine. A review of every 2023 Ohio Health Insurance Marketplace plan and Medicaid plan found that IV ketamine for depression was not covered by a single plan. Esketamine, on the other hand, appeared on nearly 73% of Marketplace formularies and 100% of Ohio Medicaid formularies.²

Ohio is one state, and formularies vary across the country, but the pattern is broadly representative. Insurers can point to the lack of an FDA depression indication as justification for excluding generic ketamine. Some patients have had success getting partial reimbursement by submitting claims with documentation of treatment-resistant depression, prior medication failures, and a letter of medical necessity from their prescriber. But this is an appeal process, not a guarantee, and most appeals are denied.

If you have insurance and want to minimize out-of-pocket costs, the most straightforward path is asking your psychiatrist about esketamine. Your psychiatrist will need to verify that you meet the criteria for treatment-resistant depression (generally defined as having failed at least two adequate antidepressant trials), then refer you to a certified Spravato treatment center. The manufacturer also operates a patient assistance program for qualifying individuals.

Telehealth and At-Home Ketamine

A growing segment of the ketamine market involves telehealth companies that prescribe sublingual or oral ketamine for at-home use. About half of the overall ketamine-for-mental-health market now involves telehealth providers using off-label prescribing.⁸ These services are often significantly cheaper than in-clinic IV infusions, sometimes offering monthly subscriptions that include the medication, virtual check-ins, and integration support.

The convenience is real, but the trade-offs matter. Ketamine is a dissociative anesthetic and a Schedule III controlled substance. When you take it at home, no medical professional is physically present to monitor your blood pressure, manage an adverse reaction, or intervene if something goes wrong. The same review that documented the growth of telehealth prescribing raised concerns about whether off-label prescribing of a dissociative anesthetic through telehealth meets the standard for appropriate controlled substance prescribing, particularly around monitoring requirements and patient safety.⁸

If you do use an at-home service, take basic precautions seriously. Have another adult present during your session. Do not combine ketamine with alcohol, benzodiazepines, or other sedatives. Sit or lie down before the medication takes effect. And make sure the prescribing provider has actually reviewed your medical history, not just a brief symptom questionnaire. Some telehealth platforms have tightened their intake processes in response to criticism, but quality varies enormously across the market.

A Typical Treatment Schedule

Most IV ketamine clinics follow a similar initial protocol: a series of six infusions spread over two to three weeks, sometimes called the “induction phase.” Not everyone responds by the second or third session, so committing to the full initial course is generally recommended before deciding whether the treatment works for you.

One retrospective study of an escalating-dose protocol with eight to ten infusion sessions found a 47% response rate for depression, with no evidence of cognitive impairment on standardized testing.⁹ The cognitive safety finding is reassuring, since many patients worry about the effects of repeated dissociative experiences on memory and thinking.

After the initial series, most patients who respond need some form of maintenance treatment. The frequency varies. Some people return monthly; others stretch intervals to every six to eight weeks. A minority of patients maintain their improvement without ongoing infusions, but this appears to be the exception. Your clinician should be adjusting the schedule based on how you are actually doing, not locking you into a fixed plan.

For esketamine, the FDA-approved schedule is twice weekly for the first month, once weekly for the second month, then once weekly or every two weeks thereafter. Each session requires the two-hour monitored observation period at a certified site.

Does Adding Psychotherapy Help

Many clinics now offer ketamine-assisted psychotherapy, or KAP, where talk therapy is integrated into the ketamine session or structured around it. The idea is intuitive: ketamine opens a window of neuroplasticity, and psychotherapy during that window might help patients process difficult material and make lasting changes.

A systematic review found that despite wide variation in how KAP is applied, combining psychotherapy before, during, and after ketamine sessions can maximize and prolong the treatment’s benefits.¹⁰ But a larger observational study painted a more nuanced picture. Looking at several hundred patients who received either ketamine alone or ketamine plus psychotherapy, both groups showed substantial improvement in depression and PTSD symptoms, with similar patterns of rapid early improvement followed by stabilization. The study found no significant differences in symptom trajectories between the two groups.¹¹

The honest read of the evidence is that it is still unsettled. Ketamine-assisted psychotherapy comes in many forms. Some approaches use the dissociative state itself as a therapeutic tool; others simply schedule psychotherapy around ketamine sessions without requiring the altered state to be central to the therapy.¹² Whether those two approaches produce different outcomes has not been rigorously tested in head-to-head trials. If a clinic charges a premium for KAP, it is worth knowing that the added psychotherapy component has not been proven to produce better depression outcomes than ketamine alone in the available data, though it may offer other benefits like better integration of the experience and more emotional support during a vulnerable period.

Side Effects and Safety Concerns

Short-term side effects during and immediately after a ketamine session are common and generally manageable. Most people experience some combination of dissociation, dizziness, nausea, increased blood pressure, and a feeling of being “out of it” for several hours. These effects typically resolve within a few hours of the session ending. Nausea can often be prevented or reduced with anti-nausea medication given before the infusion.

The more serious safety conversation involves longer-term use. The concern that draws the most clinical attention is bladder toxicity. Ketamine-induced cystitis, well documented in people who use ketamine recreationally at high doses, causes urinary pain, increased urgency and frequency, reduced bladder capacity, and in severe cases, kidney damage. Frequent recreational use has been shown to increase cystitis risk by three to four times.¹³ Stopping ketamine use usually improves symptoms, but some damage can be irreversible.¹⁴

The doses used in therapeutic settings are much lower than typical recreational abuse doses, and treatments happen far less frequently. But for patients on long-term maintenance therapy, the cumulative exposure is worth monitoring. If you develop any new urinary symptoms while receiving ketamine treatment, report them to your provider promptly rather than assuming they are unrelated. The mechanism involves direct toxic effects of ketamine metabolites on the bladder lining, causing inflammation and, over time, fibrosis of the bladder wall.¹⁵

Addiction potential is another concern, though it plays out differently than with opioids or benzodiazepines. Ketamine can be psychologically habit-forming. Patients who find relief from severe depression may understandably want more frequent doses, and the dissociative experience itself can become appealing. A responsible prescriber will set clear boundaries around dosing frequency and watch for signs of escalating use or requests for higher doses.

How Ketamine Works Differently From Other Antidepressants

Standard antidepressants like SSRIs primarily affect serotonin signaling and take weeks to produce clinical effects. Ketamine works through a different system entirely, blocking a type of receptor involved in excitatory signaling in the brain. A single sub-anesthetic dose can trigger rapid antidepressant effects, sometimes within hours, through a cascade that promotes the growth of new synaptic connections.¹⁶ This speed of action is what makes ketamine uniquely valuable for people in acute crisis or those who have not responded to conventional medications.

The rapid onset is also what makes maintenance treatment necessary for most patients. Ketamine appears to create a temporary window of enhanced neuroplasticity rather than a permanent shift in brain chemistry. When the drug is discontinued, many patients relapse within weeks to months. Researchers are actively working on extending the duration of ketamine’s effects through combination strategies and maintenance scheduling, but no one has found a way to make a single course of ketamine produce lasting remission in most patients.

Combining Ketamine With Other Treatments

Some clinics and research groups are exploring whether pairing ketamine with other interventions can improve or extend results. The most studied combination is ketamine with transcranial magnetic stimulation (TMS), a non-invasive brain stimulation technique. A systematic review found that combining TMS and ketamine produced more sustained improvement in depression than either treatment alone, with generally mild and transient side effects.¹⁷ The evidence base is still early, consisting mostly of case reports and retrospective studies rather than large randomized trials, but the direction is encouraging enough that some treatment centers now offer both modalities.

Ketamine is also typically used alongside ongoing oral antidepressants rather than as a replacement. Most clinical protocols do not ask patients to stop their existing psychiatric medications before starting ketamine, though certain drugs may need dose adjustments. If you are considering ketamine therapy, do not stop or change your current medications without guidance from the prescriber managing those medications. The goal for most patients is to use ketamine’s rapid effects to stabilize a crisis or break through treatment resistance, then continue working with conventional treatments and therapy for long-term management.